Baxter Advate
This article was originally published in The Gray Sheet
Executive Summary
Hemophilia A therapy gains FDA sign-off July 25. Shipments of the recombinant antihemophilic factor plasma/albumin-free method (rAHF-PFM) product to distributors will begin in three to six weeks. Baxter has projected that the product will help drive BioScience unit growth of 5%-10% this year (1"The Gray Sheet" July 21, 2003, p. 13)...
You may also be interested in...
Baxter Profit Pressures Lead To Expanded Restructuring, SEC Probe
Baxter expects to save $120-$160 mil. annually upon completion of a revised restructuring plan that includes the closure of 30 facilities and downsizing its workforce by 6%, or 3,200 employees
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.